Table 1.

Baseline characteristics of the patients

Characteristic, n (%)Reference ESA (n=1409)Methoxy Polyethylene Glycol-Epoetin Beta (n=1409)
Median age, yr (interquartile range)65 (53–74)64 (53–74)
Men828 (59)805 (57)
Region
 Europe1038 (74)1039 (74)
 Asia162 (11)150 (11)
 Australia73 (5)75 (5)
 Latin America136 (10)145 (10)
Treatment condition
 Correction273 (19)273 (19)
 Maintenance1136 (81)1136 (81)
On dialysis1173 (83)1194 (85)
 Years receiving dialysisn=1173n=1194
  <1290 (25)288 (24)
  1–3432 (37)429 (36)
  >3451 (38)477 (40)
 Dialysis modalityn=1173n=1194
  Peritoneal dialysis81 (7)91 (8)
  Hemodialysis1092 (93)1103 (92)
Cardiovascular risk factors and history
 Ischemic heart disease420 (30)376 (27)
 Peripheral vascular disease234 (17)200 (14)
 Cerebral vascular disease137 (10)131 (9)
 Congestive heart failure202 (14)192 (14)
  NYHA class I54 (4)47 (3)
  NYHA class II121 (9)112 (8)
  NYHA class III30 (2)41 (3)
  NYHA class IV10 (1)15 (1)
  Unknown5 (0)0 (0)
 Venous thrombosis165 (12)164 (12)
 Hypertension1267 (90)1268 (90)
 Hyperlipidemia776 (55)759 (54)
 Diabetes495 (35)496 (35)
 C-reactive protein ≤30 mg/L1288/1386 (93)1283/1379 (93)
  • There were no significant differences between the two arms with regard to any baseline characteristics. ESA, erythropoiesis-stimulating agent; NYHA, New York Heart Association.